Jim Cramer says buy Eil lily over Novo

Quote












NVO is a purer bet on obesity whereas LLY is buying a little bit of a broader bucket of diseases. Both are going to do well over the coming years, but you also have to take into account that a lot of the future growth in this space is already priced into the stock.

Why not own both?
 




































anonymous said:
Inverse Cramer ftw
Click to expand...

exactly. Anyone who listens to that nut deserves everything they get.

As I said prior, NVO is the purer play on diabesity and sure enough, LLY had a setback with an Alzheimer’s drug this week which sent their stock down.

Mounjaro formidable but LLY needs more than that, given the broader range of products they have.
 






anonymous said:
exactly. Anyone who listens to that nut deserves everything they get.

As I said prior, NVO is the purer play on diabesity and sure enough, LLY had a setback with an Alzheimer’s drug this week which sent their stock down.

Mounjaro formidable but LLY needs more than that, given the broader range of products they have.
Click to expand...
Umm….can you even read stock analyses? Just look at Lilly vs Novo in any time period and see the comparison in stock increases.
 






anonymous said:
exactly. Anyone who listens to that nut deserves everything they get.

As I said prior, NVO is the purer play on diabesity and sure enough, LLY had a setback with an Alzheimer’s drug this week which sent their stock down.

Mounjaro formidable but LLY needs more than that, given the broader range of products they have.
Click to expand...
From Fiercepharma
Eli Lilly to pour $450M more into diabetes drug plant in North Carolina, add 100 jobs
 






anonymous said:
NVO is a purer bet on obesity whereas LLY is buying a little bit of a broader bucket of diseases. Both are going to do well over the coming years, but you also have to take into account that a lot of the future growth in this space is already priced into the stock.

Why not own both?
Click to expand...

agree, there will be an ebb and flow between the two for many years but best to invest in both companies if you can!
 






anonymous said:
Umm….can you even read stock analyses? Just look at Lilly vs Novo in any time period and see the comparison in stock increases.
Click to expand...
I can. Can you? NVO beats LLY over last week, month, YTD, 1 year, and since inception. LLY beats novo in the medium range (~5 years).

What we are talking about here is not the past, though. We are talking about the market going forward as it relates to betting on obesity.
 






From Barrons: Eli Lilly rose 33% and Novo Nordisk rose 25% last year behind sales of the first drugs found to cause dramatic weight loss.
Yeah and just google the 5 year difference.
You’re just sad and stupid. Keep trading your stocks based on Day or Month gains/losses. You must be a millionaire.
You must get a lot of your rooms comped at the Travelodge in Las Vegas

Two of last year’s strongest drug stocks were energized by weight loss.

While the overall equity market sagged in 2022, Eli Lilly (ticker: LLY) rose by 33% and Novo Nordisk (NVO) rose 25%. Much of the excitement was inspired by their lead in a class of drugs known as incretins.
 






anonymous said:
From Barrons: Eli Lilly rose 33% and Novo Nordisk rose 25% last year behind sales of the first drugs found to cause dramatic weight loss.
Yeah and just google the 5 year difference.
You’re just sad and stupid. Keep trading your stocks based on Day or Month gains/losses. You must be a millionaire.
You must get a lot of your rooms comped at the Travelodge in Las Vegas

Two of last year’s strongest drug stocks were energized by weight loss.

While the overall equity market sagged in 2022, Eli Lilly (ticker: LLY) rose by 33% and Novo Nordisk (NVO) rose 25%. Much of the excitement was inspired by their lead in a class of drugs known as incretins.
Click to expand...

Wow, you still have to look at articles and can’t compare charts yourself. Nice. Go have another look and get back to me.

And again, we’re not talking about historical performance anyway. We’re talking about future performance. Let’s revisit this in 5 years and see who is right.

Ps: I played this game with the “Tersiba” $57 stock guy years ago and was right then, too. Because he was also a moron.
 






Top Bottom
Back
Quote